Grünenthal appoints Gabriel Baertschi as Chairman and Chief Executive

He follows Prof. Dr Eric-Paul Paques who retires after 23 years with the company

German pharmaceutical firm Grünenthal Group has named Gabriel Baertschi to become CEO as of 1 October.

Baertschi will join Grünenthal from AstraZeneca, where he is currently country president for Japan. He succeeds Prof. Dr Eric-Paul Pâques.

Baertschi has more than 17 years of international experience in the pharmaceutical industry. Prior to his current role at AstraZeneca, he was country president for Germany and earlier in his career was country manager in various emerging markets.

During the last quarter of 2016, both Pâques and Baertschi will work together to ensure a smooth transition. Under Pâques' leadership, Grünenthal has significantly expanded its global business, especially in Latin America, Europe as well as the US by bringing new innovative treatments to market, and sharpened its strategy with regards to R&D and partnering and growing new promising business areas such as the hospital business.

You may also like

Research & Development

Catalent and Grünenthal announce manufacturing collaboration

In this phase, Catalent supported Grünenthal with the development of a bioavailability enhanced formulation
Finance

Grünenthal Group agrees to buy Almirall's operations in Mexico

The deal is a key element of the German Group's strategy to strengthen its footprint in Latin America
Finance

Gruenenthal completes acquisition of Empresas Andromaco

Almost doubles sales in Latin America
Research & Development

Xention and Grünenthal sign research agreement

To focus on new drugs to treat chronic pain
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Subscribe now